Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report)'s stock price was up 3.9% during trading on Wednesday . The company traded as high as $19.73 and last traded at $19.63. Approximately 425,420 shares changed hands during trading, a decline of 18% from the average daily volume of 516,040 shares. The stock had previously closed at $18.90.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on NRIX shares. UBS Group started coverage on Nurix Therapeutics in a report on Thursday, October 24th. They issued a "buy" rating and a $35.00 target price on the stock. Jefferies Financial Group initiated coverage on Nurix Therapeutics in a research note on Friday, October 11th. They issued a "buy" rating and a $41.00 price target on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $29.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, December 10th. Stephens reissued an "overweight" rating and issued a $31.00 target price on shares of Nurix Therapeutics in a research report on Monday, October 14th. Finally, Royal Bank of Canada decreased their price objective on shares of Nurix Therapeutics from $27.00 to $26.00 and set an "outperform" rating for the company in a research note on Monday, October 14th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat, Nurix Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $30.35.
Get Our Latest Research Report on Nurix Therapeutics
Nurix Therapeutics Stock Performance
The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of -6.70 and a beta of 2.14. The business's 50 day moving average is $21.92 and its 200-day moving average is $22.53.
Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.67). The company had revenue of $12.59 million for the quarter, compared to the consensus estimate of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. Equities research analysts forecast that Nurix Therapeutics, Inc. will post -2.81 EPS for the current fiscal year.
Insider Activity
In related news, CFO Houte Hans Van sold 3,546 shares of the stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $24.28, for a total value of $86,096.88. Following the completion of the sale, the chief financial officer now owns 33,724 shares in the company, valued at approximately $818,818.72. This trade represents a 9.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Christine Ring sold 3,290 shares of Nurix Therapeutics stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $25.00, for a total value of $82,250.00. Following the sale, the insider now directly owns 24,592 shares in the company, valued at approximately $614,800. This trade represents a 11.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 12,641 shares of company stock valued at $309,408. 7.20% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. Driehaus Capital Management LLC acquired a new position in shares of Nurix Therapeutics in the 2nd quarter valued at $26,778,000. Samlyn Capital LLC acquired a new stake in Nurix Therapeutics in the 2nd quarter valued at $12,177,000. Sumitomo Mitsui Trust Group Inc. acquired a new position in Nurix Therapeutics during the third quarter worth $12,432,000. FMR LLC lifted its holdings in shares of Nurix Therapeutics by 675.9% during the third quarter. FMR LLC now owns 586,902 shares of the company's stock valued at $13,188,000 after acquiring an additional 511,256 shares during the period. Finally, Lord Abbett & CO. LLC acquired a new stake in shares of Nurix Therapeutics in the 3rd quarter valued at $7,879,000.
Nurix Therapeutics Company Profile
(
Get Free Report)
Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
See Also
Before you consider Nurix Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nurix Therapeutics wasn't on the list.
While Nurix Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
